Strongbridge Bio Ord (SBBP)

2  +0.03 (+1.52%)

After market: 2.02 +0.02 (+1%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SBBP. SBBP was compared to 197 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SBBP have multiple concerns. SBBP is valued quite expensively, but it does show have an excellent growth rating.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SBBP has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -41.48%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -124.18%
PM (TTM) -115.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for SBBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

SBBP has an Altman-Z score of -3.75. This is a bad value and indicates that SBBP is not financially healthy and even has some risk of bankruptcy.
SBBP has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z -3.75
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

SBBP has a Current Ratio of 3.00. This indicates that SBBP is financially healthy and has no problem in meeting its short term obligations.
SBBP has a Quick Ratio of 2.95. This indicates that SBBP is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3
Quick Ratio 2.95

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.38% over the past year.
SBBP shows a strong growth in Revenue. In the last year, the Revenue has grown by 34.98%.
The Revenue has been growing by 63.38% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)49.38%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q41.67%
Revenue 1Y (TTM)34.98%
Revenue growth 3Y63.38%
Revenue growth 5YN/A
Revenue growth Q2Q29.41%

3.2 Future

SBBP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.82% yearly.
The Revenue is expected to grow by 45.58% on average over the next years. This is a very strong growth
EPS Next Y35.78%
EPS Next 2Y29.57%
EPS Next 3Y42.71%
EPS Next 5Y34.82%
Revenue Next Year25.01%
Revenue Next 2Y38.84%
Revenue Next 3Y42.39%
Revenue Next 5Y45.58%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SBBP. In the last year negative earnings were reported.
Also next year SBBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.36

4.3 Compensation for Growth

A more expensive valuation may be justified as SBBP's earnings are expected to grow with 42.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.57%
EPS Next 3Y42.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SBBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Strongbridge Bio Ord

NASDAQ:SBBP (10/5/2021, 7:21:57 PM)

After market: 2.02 +0.02 (+1%)

2

+0.03 (+1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap135.66M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.48%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -124.18%
PM (TTM) -115.66%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3
Quick Ratio 2.95
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)49.38%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y35.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)34.98%
Revenue growth 3Y63.38%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y